Genetic Testing and Counseling

Genetic testing is where the invisible molecular architecture of a person becomes clinically actionable information — a diagnosis confirmed, a risk quantified, a treatment chosen, or a reproductive decision informed. But a laboratory result is only half the story. A gene variant does not tell a family what it means for their child, their pregnancy, or their siblings. That translation — from probability and molecular fact into a decision the patient owns — is the work of genetic counseling. This page teaches both together, because in real medicine they are inseparable: you should never order a genetic test you are not prepared to help someone understand.

For a student, this is one of the most exam-heavy and clinically relevant corners of medical genetics, and one where the ethics matter as much as the biology.

Learning Objectives

• Classify genetic tests by purpose (diagnostic, predictive, carrier, prenatal, newborn, pharmacogenomic) and by method (karyotype, FISH, chromosomal microarray, targeted, panels, exome/genome).
• Distinguish screening from diagnostic testing and explain why a positive screen is never a diagnosis.
• Describe the structure and non-directive philosophy of genetic counseling, including pre- and post-test counseling.
• Explain the history and motivation behind newborn screening and prenatal testing.
• Interpret core concepts: sensitivity/specificity, positive predictive value, variants of uncertain significance, and incidental findings.
• Recognise the major ethical and legal issues (consent, testing children, privacy, genetic discrimination).

Quick Answer

Genetic testing analyses chromosomes, genes, or gene products to diagnose disease, predict future risk, identify carriers, or guide therapy. Tests range from whole-chromosome methods (karyotype, chromosomal microarray) to single-gene and genome-wide sequencing. A crucial distinction is screening (applied to a broad, often asymptomatic population to flag those needing further work-up) versus diagnostic testing (confirms or excludes a specific condition in an individual). Screening tests are tuned for high sensitivity, so a positive result must be confirmed diagnostically. Genetic counseling wraps around all of this: a trained counselor gathers a family history, explains risks and options, obtains informed consent, and supports the patient in reaching their own decision — a stance called non-directiveness. Newborn screening (born from PKU testing in the 1960s) and prenatal testing (amniocentesis and later cell-free DNA) are the two historic pillars of population genetic testing.

Where It Came From

The need was concrete and heartbreaking: children born healthy who deteriorated into irreversible disability before anyone knew why. Phenylketonuria (PKU) is the founding story. In 1934 the Norwegian physician Asbjørn Følling identified that certain children with intellectual disability excreted phenylpyruvic acid in their urine — a metabolic block in processing the amino acid phenylalanine. The tragedy was that if the block was caught at birth and the child put on a low-phenylalanine diet, normal development followed. The disability was preventable, but only if detected before symptoms appeared. In the early 1960s Robert Guthrie developed a cheap bacterial-inhibition assay that could screen a dried blood spot from a heel prick. Suddenly whole populations of newborns could be tested for a few cents each. This is the origin of the Guthrie card and of newborn screening as public health policy — the first time genetics was applied to entire populations rather than sick individuals.

Prenatal testing answered a different need: parents at known risk (advanced maternal age, a prior affected child, a family history) who wanted information about a current pregnancy. Amniocentesis was used diagnostically for fetal karyotyping from the late 1960s, and chorionic villus sampling (CVS) followed in the 1980s, offering earlier (first-trimester) results. Both are invasive and carry a small miscarriage risk, which drove the search for safer methods. The breakthrough came from a 1997 discovery by Dennis Lo that cell-free fetal DNA circulates in maternal blood. This launched non-invasive prenatal testing (NIPT) around 2011 — a screening blood test with high detection rates for Down syndrome and other common aneuploidies, no procedure-related miscarriage risk.

Meanwhile, the profession of genetic counseling was formalised — the first master's program opened at Sarah Lawrence College in 1969 — precisely because the old eugenic, directive style of "advising" families was recognised as unethical. The modern discipline is deliberately non-directive: it exists to inform and support autonomous choice, not to steer reproduction. The Human Genome Project (completed 2003) and the collapse in sequencing cost since then turned single-gene tests into affordable panels and whole-exome sequencing, expanding testing from rare syndromes into everyday oncology, cardiology, and pharmacology.

Types of Genetic Tests

Genetic tests can be organised two ways — by why you order them (purpose) and by how the lab does it (method). Exams love both.

By purpose:

• Diagnostic testing — confirms or rules out a suspected condition in a symptomatic patient (e.g., sequencing CFTR in a child with recurrent chest infections and failure to thrive suggesting cystic fibrosis).
• Predictive / presymptomatic testing — tests an asymptomatic person at risk of a later-onset condition. Presymptomatic means a positive result is essentially certain to cause disease (e.g., HTT expansion in Huntington disease). Predisposition testing gives a raised probability, not certainty (e.g., BRCA1/2 and breast/ovarian cancer risk).
• Carrier testing — identifies healthy people who carry one copy of a recessive variant. Relevant for reproductive planning (e.g., cystic fibrosis, thalassaemia, Tay–Sachs, spinal muscular atrophy).
• Prenatal testing — assesses a fetus (screening: NIPT, combined first-trimester screen; diagnostic: CVS, amniocentesis).
• Newborn screening — population screening of neonates for treatable conditions.
• Preimplantation genetic testing (PGT) — tests embryos created by IVF before transfer.
• Pharmacogenomic testing — predicts drug response or toxicity (e.g., HLA-B*57:01 before abacavir; TPMT/NUDT15 before thiopurines; DPYD before fluoropyrimidines).

By method:

Method	Resolution / detects	Typical use
Karyotype	Whole chromosomes, large (~5–10 Mb) changes, aneuploidy, translocations	Down syndrome, balanced translocations, recurrent miscarriage
FISH	A specific chromosomal region	Rapid aneuploidy, microdeletions (e.g., 22q11.2), HER2
Chromosomal microarray (CMA)	Copy-number gains/losses genome-wide (higher resolution than karyotype)	First-line for unexplained developmental delay, autism, congenital anomalies
Targeted variant / single gene	One known variant or one gene	Known familial variant, sickle cell, Huntington
Gene panel	Many genes at once	Hereditary cancer, cardiomyopathy, epilepsy
Whole-exome / whole-genome sequencing	All coding regions / entire genome	Undiagnosed disease, atypical presentations

A key limitation: karyotype and CMA do not detect small single-nucleotide changes, and CMA does not detect balanced translocations (no gain or loss of material). Sequencing detects small variants but standard panels may miss large deletions or repeat expansions. Choosing the method is a diagnostic art — the counselor and clinician match the test to the suspected mechanism.

Screening Versus Diagnostic Testing

This distinction is the single most tested idea in the topic, and the most consequential clinically.

A screening test is applied to a large group — often asymptomatic — to identify the subset who need further evaluation. It is deliberately tuned for high sensitivity (catch nearly everyone affected) accepting more false positives. A diagnostic test is applied to an individual to confirm or exclude a condition with high specificity.

Because screening operates in low-prevalence populations, even an excellent screen has a modest positive predictive value (PPV) — the proportion of positive results that are true. This is why a positive screen is never a diagnosis.

Worked example — NIPT for Down syndrome. Suppose NIPT has ~99% sensitivity and ~99.9% specificity, and in a 25-year-old the prevalence of trisomy 21 is roughly 1 in 1,000. Imagine 100,000 such pregnancies:

• True affected: 100. NIPT detects ~99.
• Unaffected: 99,900. False positives at 0.1% = ~100.
• Positive results total ≈ 199, of which ~99 are true.
• PPV ≈ 99 / 199 ≈ 50%.

So in a low-risk young woman, a "positive" NIPT is right only about half the time — which is exactly why NIPT is a screen, and a positive result must be confirmed by diagnostic amniocentesis or CVS before any irreversible decision. The same PPV, in a 40-year-old whose baseline risk is far higher, would be much greater — PPV depends on pre-test probability. Teaching a family this is a central counseling task.

The Role of Genetic Counseling

Genetic counseling is a communication process, delivered by certified genetic counselors or clinical geneticists, that helps people understand and adapt to the medical, psychological, and familial implications of genetic conditions. Its defining ethic is non-directiveness: the counselor provides balanced information and supports the patient's own values-based decision rather than recommending a particular reproductive or testing choice.

A typical consultation:

1. Contracting and history — clarify what the patient wants; take a detailed three-generation pedigree.
2. Risk assessment — using the pedigree, inheritance pattern, and any prior results, estimate recurrence or occurrence risk.
3. Pre-test counseling — explain the test's purpose, what results (positive, negative, VUS) could mean, limitations, cost, and downstream implications for the patient and relatives; obtain informed consent. For predictive tests like Huntington, this may span multiple visits with psychological support.
4. Testing — with consent.
5. Post-test counseling — deliver and interpret results, discuss management, screening, reproductive options, and cascade testing of at-risk relatives.
6. Support and follow-up — psychosocial support and referral.

Case vignette. A 32-year-old woman whose mother and maternal aunt both had breast cancer before age 45 is referred. The pedigree suggests dominant, high-penetrance risk. Pre-test counseling covers what a BRCA1/2 pathogenic variant would mean (enhanced surveillance, risk-reducing surgery, implications for her sister and daughters), what a VUS would mean (uncertain — do not act on it), and psychological impact. She consents; a pathogenic BRCA1 variant is found. Post-test, the counselor arranges MRI surveillance, discusses risk-reducing mastectomy and salpingo-oophorectomy, and facilitates cascade testing — offering testing to her at-risk relatives, who can then have a simple, cheap targeted test for the known family variant.

Real-World Applications

• Reproductive medicine: expanded carrier screening for couples, PGT for known familial variants, prenatal diagnosis.
• Oncology: hereditary cancer panels (BRCA, Lynch syndrome) drive surveillance and prophylactic surgery; tumour genomics guides targeted therapy.
• Cardiology: genetic testing in inherited cardiomyopathies and channelopathies (long QT) identifies at-risk relatives who need monitoring.
• Pharmacogenomics: avoiding abacavir hypersensitivity (HLA-B*57:01), dosing thiopurines and 5-FU safely.
• Public health: newborn screening prevents disability from PKU, congenital hypothyroidism, cystic fibrosis, and (increasingly) spinal muscular atrophy, where early treatment is transformative.
• Undiagnosed disease: exome/genome sequencing ends long "diagnostic odysseys" for children with rare disorders.

Common Mistakes

1. Treating a positive screen as a diagnosis. Why wrong: screens have imperfect PPV, especially in low-risk populations. Correction: always confirm a positive screen (e.g., positive NIPT) with a diagnostic test before any irreversible action.
2. Assuming a negative test means "no risk." Why wrong: a negative gene-panel result can be a false reassurance — the causative gene may not be on the panel, the variant type may be undetectable by that method, or the condition may be non-genetic. A negative test in someone with a strong family history but no identified familial variant is uninformative, not protective. Correction: interpret negatives in light of the test's scope and the family history.
3. Acting on a variant of uncertain significance (VUS). Why wrong: a VUS is, by definition, not proven to be disease-causing; many are later reclassified as benign. Correction: do not base surgery or reproductive decisions on a VUS; manage the patient on clinical/family-history grounds and re-evaluate as evidence accumulates.
4. Testing children for adult-onset conditions. Why wrong: it removes the child's future autonomy and offers no childhood benefit for untreatable adult conditions. Correction: generally defer predictive testing for adult-onset disease (e.g., Huntington) until the person can consent as an adult, unless childhood intervention would help.

Comparison and Connections

Feature	Screening test	Diagnostic test
Population	Broad, often asymptomatic	Individual with symptoms or a positive screen
Tuned for	High sensitivity	High specificity / confirmation
Result meaning	Flags who needs further testing	Confirms or excludes the condition
Example (prenatal)	NIPT, combined first-trimester screen	CVS, amniocentesis
Consequence of positive	Offer diagnostic test	Basis for management decision

Related concept comparisons: Predictive vs diagnostic — diagnostic tests explain existing symptoms; predictive tests estimate future disease in the well. Carrier vs affected — a carrier of a recessive variant is healthy but can pass it on. NIPT vs amniocentesis — NIPT is a safe screen from maternal blood; amniocentesis is the invasive diagnostic gold standard with a small procedure-related risk.

For the underlying rules of how variants pass through families, see the topic on inheritance patterns in this branch (../index.md), and connect to hereditary cancer in ../../32._Oncology/index.md.

Practice Questions

Recall

Q: What is the difference between carrier testing and diagnostic testing? A: Carrier testing identifies a healthy person who carries one copy of a recessive variant (relevant to reproductive risk); diagnostic testing confirms or excludes a suspected condition in a person who may be symptomatic.

Understanding

Q: Why must a positive NIPT result be confirmed before any irreversible decision? A: NIPT is a screening test with imperfect positive predictive value, especially in low-risk women where most positives can be false. Only a diagnostic test (CVS or amniocentesis) can confirm the fetal chromosomal status.

Application

Q: A couple are both found to be carriers of a cystic fibrosis variant. What is the recurrence risk for each pregnancy, and what options can a counselor discuss? A: As an autosomal recessive condition, each pregnancy has a 1 in 4 (25%) risk of an affected child. Options include prenatal diagnosis (CVS/amniocentesis), preimplantation genetic testing with IVF, use of donor gametes, adoption, or accepting the risk — presented non-directively.

Analysis

Q: A whole-exome sequence for a child's developmental delay incidentally reveals a pathogenic BRCA2 variant. What issues does this raise? A: This is a secondary/incidental finding — medically actionable but unrelated to the reason for testing. Issues: whether it was consented to before testing, implications for the child's parents (one likely carries it) and future autonomy, and whether reporting adult-onset cancer risk in a child is appropriate. It should be handled within a pre-agreed policy on secondary findings and returned via genetic counseling.

FAQ

Is a genetic test result private, or can insurers use it? In many jurisdictions, laws (such as GINA in the United States) restrict genetic discrimination in health insurance and employment, but protections vary and may not cover life or disability insurance. This is a real counseling concern and should be discussed pre-test.

If my test is negative, does that mean my children are safe? Not necessarily. A negative result only excludes what the test looked for. If no familial variant has been identified, a negative in an at-risk person may be uninformative. Interpretation depends on the test's scope and your family history.

What is a "variant of uncertain significance"? It is a DNA change whose effect on health is not yet known. It is neither confirmed harmful nor confirmed benign, and it should not drive medical decisions. Many VUS are eventually reclassified, usually as benign.

Should I test my healthy child for an adult-onset condition in the family? Generally no, if there is no childhood benefit and the condition is untreatable in childhood. Deferring preserves the child's right to decide as an adult. Testing is appropriate when early monitoring or treatment helps.

How is NIPT different from an amniocentesis? NIPT is a screening blood test on the mother that analyses cell-free fetal DNA — safe, but not diagnostic. Amniocentesis samples amniotic fluid to test fetal cells directly — it is diagnostic but carries a small miscarriage risk. A positive NIPT is confirmed by amniocentesis or CVS.

Do I need a genetic counselor, or can my doctor just order the test? Any clinician can order many tests, but genetic counseling ensures you understand the implications, give informed consent, and receive support interpreting results — particularly important for predictive, prenatal, and cancer-risk testing.

Quick Revision

• Tests classified by purpose (diagnostic, predictive, carrier, prenatal, newborn, PGT, pharmacogenomic) and method (karyotype, FISH, CMA, targeted, panel, exome/genome).
• Screening = high sensitivity, broad population, flags who needs work-up; diagnostic = confirms in the individual.
• A positive screen is never a diagnosis — PPV depends on pre-test probability.
• Newborn screening began with Guthrie's PKU test (1960s); prenatal testing evolved amniocentesis → CVS → NIPT (cell-free DNA, Dennis Lo 1997).
• Genetic counseling is non-directive: pedigree, risk assessment, pre-test consent, post-test interpretation, cascade testing, support.
• Beware: false reassurance from negatives, acting on a VUS, and testing children for adult-onset disease.
• Incidental/secondary findings and genetic privacy (GINA) are core ethical issues.

Related Topics

Prerequisites

• Medical Genetics overview
• Basics of inheritance patterns (see this branch: ../index.md)

Related Topics

• Hereditary cancer syndromes — ../../32._Oncology/index.md
• Community and public health screening principles — ../../8._Community_Medicine/index.md

Next Topics

• Pharmacogenomics and personalised medicine (see this branch: ../index.md)
• Prenatal diagnosis and reproductive genetics (see this branch: ../index.md)